Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20663619 | 0.66 | GAA (0.31) | MAPT | |
| SCHEMBL31095199 | 0.62 | GAA (0.44) | KDM4CKDM4EALDH1A1MAPTKDM5B | |
| Acetic Acid SCHEMBL28280160 | 0.61 | KDM4C (0.33) | KDM4CKDM4EALDH1A1MAPTKDM6B | |
| SCHEMBL6166481 | 0.61 | HSD11B1 (0.42) | ALDH1A1 | |
| SCHEMBL16432722 | 0.59 | KDM4C (0.39) | KDM4CKDM4EALDH1A1MAPTKDM6B | |
| SCHEMBL4654925 | 0.58 | ALDH1A1 (0.32) | KDM4CKDM4EALDH1A1MAPTKDM6B | |
| SCHEMBL30440354 | 0.56 | KDM4C (0.36) | KDM4CKDM4EALDH1A1MAPTKDM6B | |
| SCHEMBL8366169 | 0.56 | KDM4C (0.36) | KDM4CKDM4EALDH1A1MAPTKDM6B | |
| SCHEMBL12324803 | 0.55 | — | — | |
| SCHEMBL16187249 | 0.55 | GAA (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | KDM4C 3537/4885CDC7 332/4885DBF4 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.